Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | SMO | Q99835 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33952 | 0.95 | ALDH1A1 (0.56) | ALDH1A1CES2CES1SMOPOLB | |
| SCHEMBL3138767 | 0.89 | CES2 (0.54) | ALDH1A1CES2CES1SMOPOLB | |
| SCHEMBL4416667 | 0.84 | CES2 (0.62) | ALDH1A1CES2CES1POLBHPGD | |
| SCHEMBL7863427 | 0.80 | GSK3B (0.52) | ALDH1A1CES2CES1SMOPOLB | |
| SCHEMBL8797736 | 0.78 | ALDH1A1 (0.54) | ALDH1A1CES2CES1SMOPOLB | |
| SCHEMBL5230539 | 0.78 | ALDH1A1 (0.41) | ALDH1A1HPGDNPC1GAAPKM | |
| SCHEMBL29434816 | 0.76 | KMT2A (0.65) | ALDH1A1CES2CES1SMOPOLB | |
| SCHEMBL20659154 | 0.76 | ALDH1A1 (0.52) | ALDH1A1CES2CES1SMOPOLB | |
| SCHEMBL49873 | 0.76 | KMT2A (0.65) | ALDH1A1CES2CES1SMOPOLB | |
| SCHEMBL5623439 | 0.75 | ALDH1A1 (0.46) | ALDH1A1CES2CES1GAAKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113651875-B | Oligopeptide-34 synthesis method | 南京莱昂生物科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-113651875-A | Oligopeptide-34 synthesis method | 南京莱昂生物科技有限公司 | 2021-11-16 | — | — | CN | claimed |
| EP-3431490-B1 | CHEMICAL COMPOUNDS FOR USE AS DIAGNOSTIC MARKERS OF INFLAMMATION AND NEOPLAMS, THE METHOD FOR SYNTHESIS OF THE CHEMICAL COMPOUNDS, DIAGNOSTIC KIT FOR USE IN DIAGNOSIS OF INFLAMMATORY PROCESSES AND EPITHELIAL NEOPLASMS AND IN VITRO DIAGNOSTIC METHOD OF INFLAMMATORY PROCESSES AND EPITHELIAL NEOPLASMS | UNIV GDANSKI (PL) | 2020-03-11 | — | — | EP | claimed |
| WO-2020017984-A1 | CHEMICAL COMPOUNDS FOR USE AS DIAGNOSTIC MARKERS OF INFLAMMATION AND NEOPLASMS | UNIWERSYTET GDANSKI (PL) | 2020-01-23 | — | — | WO | claimed |
| CN-110551180-A | Multifunctional implant with response effect and preparation method and application thereof | UNIV SOUTH CHINA TECH | 2019-12-10 | — | — | CN | claimed |
| EP-3431490-A1 | CHEMICAL COMPOUNDS FOR USE AS DIAGNOSTIC MARKERS OF INFLAMMATION AND NEOPLAMS, THE METHOD FOR SYNTHESIS OF THE CHEMICAL COMPOUNDS, DIAGNOSTIC KIT FOR USE IN DIAGNOSIS OF INFLAMMATORY PROCESSES AND EPITHELIAL NEOPLASMS AND IN VITRO DIAGNOSTIC METHOD OF INFLAMMATORY PROCESSES AND EPITHELIAL NEOPLASMS | Uniwersytet Gdanski (PL) | 2019-01-23 | — | — | EP | claimed |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-20240199701-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-20 | — | — | US | disclosed |
| CN-118159549-A | Immunomodulators | 百时美施贵宝公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118076623-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024102752-A1 | SMALL MOLECULE MODULATORS OF PAR2 AND USES THEREOF | PARMEDICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| US-11952379-B2 | Small molecule modulators of PAR2 and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-04-09 | — | — | US | disclosed |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| EP-0932617-B1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMA (US) | 2002-01-16 | — | — | EP | disclosed |
| EP-1136498-A1 | Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease | Vertex Pharmaceuticals Incorporated (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6265380-B1 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | VERTEX PHARMACEUTICALS INCORPORATED | 2001-07-24 | — | — | US | disclosed |
| WO-2001046125-A2 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| EP-0932617-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 1999-08-04 | — | — | EP | disclosed |
| US-5922890-A | TRITYL AMIDE OR ACID LINKERS FOR SOLID PHASE SYNTHESIS | NOVARTIS AG (CH) | 1999-07-13 | — | — | US | disclosed |
| WO-1998017679-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199701-A1 | IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | ALDH1A1 3723/4885CES2 4877/4885CES1 4471/4885 |
| US-11952379-B2 | Small molecule modulators of PAR2 and uses thereof | F2RL1, F2R, TBXA2R | ALDH1A1 3448/4885CES2 2392/4885CES1 2454/4885 |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | ALDH1A1 4678/4885CES2 4511/4885CES1 4263/4885 |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, MTOR, FKBP14 | ALDH1A1 4631/4885CES2 4581/4885CES1 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.